This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Karp, J. E. Articles by Garrett-Mayer, E. PubMed PubMed Citation Articles by Karp, J. E. Articles by Garrett-Mayer, E.

Phase II Trial of Tipifarnib as Maintenance Therapy in First Complete Remission in Adults with Acute Myelogenous Leukemia and Poor-Risk Features

Authors' Affiliations: ¹ Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; ² University of Maryland Greenebaum Cancer Center, Baltimore, Maryland; ³ Moffitt Cancer Center, University of South Florida, Tampa, Florida; ⁴ Bone Marrow Transplant Group of Georgia, Atlanta, Georgia; and ⁵ Investigational Drug Branch, Clinical Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland

Requests for reprints: Judith E. Karp, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB 1 Room 289, Baltimore, MD 21231-1000. Phone: 410-502-5399; Fax: 410-614-1005; E-mail: jkarp2{at}jhmi.edu.

Purpose: Acute myelogenous leukemia (AML) does not have a high cure rate, particularly in patients with poor-risk features. Such patients might benefit from additional therapy in complete remission (CR). Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML. We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk AML in first CR.

Experimental Design: Tipifarnib 400 mg twice daily for 14 of 21 days was initiated after recovery from consolidation chemotherapy, for a maximum of 16 cycles (48 weeks).

Results: Twenty (42%) patients completed 16 cycles, 24 (50%) were removed from study for relapse, and 4 (8%) discontinued drug prematurely for intolerance. Nonhematologic toxicities were rare, but tipifarnib dose was reduced in 58% for myelosuppression. Median disease-free survival (DFS) was 13.5 months (range, 3.5-59+ months), with 30% having DFS >2 years. Comparison of CR durations for 25 patients who received two-cycle timed sequential therapy followed by tipifarnib maintenance with 23 historically similar patients who did not receive tipifarnib showed that tipifarnib was associated with DFS prolongation for patients with secondary AML and adverse cytogenetics.

Conclusions: This study suggests that some patients with poor-risk AML, including patients with secondary AML and adverse cytogenetics, may benefit from tipifarnib maintenance therapy. Future studies are warranted to examine alternative tipifarnib dosing and continuation beyond 16 cycles.

This article has been cited by other articles:

				W. P. Vaughan and J. E. Karp The Long Road to a Cure for Acute Myelocytic Leukemia: From Intensity to Specificity J. Clin. Oncol., July 20, 2008; 26(21): 3475 - 3477. [Full Text] [PDF]